当前位置: 首页 >> 检索结果
1941. Autologous bone marrow-derived stem-cell transfer in patients with ST-segment elevation myocardial infarction: double-blind, randomised controlled trial.
作者: Stefan Janssens.;Christophe Dubois.;Jan Bogaert.;Koen Theunissen.;Christophe Deroose.;Walter Desmet.;Maria Kalantzi.;Lieven Herbots.;Peter Sinnaeve.;Joseph Dens.;Johan Maertens.;Frank Rademakers.;Steven Dymarkowski.;Olivier Gheysens.;Johan Van Cleemput.;Guy Bormans.;Johan Nuyts.;Ann Belmans.;Luc Mortelmans.;Marc Boogaerts.;Frans Van de Werf.
来源: Lancet. 2006年367卷9505期113-21页
The benefit of reperfusion therapies for ST-elevation acute myocardial infarction (STEMI) is limited by post-infarction left-ventricular (LV) dysfunction. Our aim was to investigate the effect of autologous bone marrow-derived stem cell (BMSC) transfer in the infarct-related artery on LV function and structure.
1942. Etanercept and clinical outcomes, fatigue, and depression in psoriasis: double-blind placebo-controlled randomised phase III trial.
作者: Stephen Tyring.;Alice Gottlieb.;Kim Papp.;Ken Gordon.;Craig Leonardi.;Andrea Wang.;Deepa Lalla.;Michael Woolley.;Angelika Jahreis.;Ralph Zitnik.;David Cella.;Ranga Krishnan.
来源: Lancet. 2006年367卷9504期29-35页
Psoriasis has substantial psychological and emotional effects. We assessed the effect of etanercept, an effective treatment for the clinical symptoms of psoriasis, on fatigue and symptoms of depression associated with the condition.
1943. Duration of protection with RTS,S/AS02A malaria vaccine in prevention of Plasmodium falciparum disease in Mozambican children: single-blind extended follow-up of a randomised controlled trial.
作者: Pedro L Alonso.;Jahit Sacarlal.;John J Aponte.;Amanda Leach.;Eusebio Macete.;Pedro Aide.;Betuel Sigauque.;Jessica Milman.;Inacio Mandomando.;Quique Bassat.;Caterina Guinovart.;Mateu Espasa.;Sabine Corachan.;Marc Lievens.;Margarita M Navia.;Marie-Claude Dubois.;Clara Menendez.;Filip Dubovsky.;Joe Cohen.;Ricardo Thompson.;W Ripley Ballou.
来源: Lancet. 2005年366卷9502期2012-8页
RTS,S/AS02A is a pre-erythrocytic stage malaria vaccine that provides partial protection against infection in malaria-naive adult volunteers and hyperimmune adults. A previous report showed that this vaccine reduced risk of clinical malaria, delayed time to new infection, and reduced episodes of severe malaria over 6 months in African children. An important remaining issue is the durability of protection against clinical disease in these children.
1944. Adherence to candesartan and placebo and outcomes in chronic heart failure in the CHARM programme: double-blind, randomised, controlled clinical trial.
作者: Bradi B Granger.;Karl Swedberg.;Inger Ekman.;Christopher B Granger.;Bertil Olofsson.;John J V McMurray.;Salim Yusuf.;Eric L Michelson.;Marc A Pfeffer.; .
来源: Lancet. 2005年366卷9502期2005-11页
Chronic heart failure (CHF) is an important cause of hospital admission and death. Poor adherence to medication is common in some chronic illnesses and might reduce the population effectiveness of proven treatments. Because little is known about adherence in patients with CHF and about the consequences of non-adherence, we assessed the association between adherence and clinical outcome in the CHARM (Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity) programme.
1945. Definition of subtypes of essential thrombocythaemia and relation to polycythaemia vera based on JAK2 V617F mutation status: a prospective study.
作者: Peter J Campbell.;Linda M Scott.;Georgina Buck.;Keith Wheatley.;Clare L East.;Joanne T Marsden.;Audrey Duffy.;Elaine M Boyd.;Anthony J Bench.;Mike A Scott.;George S Vassiliou.;Donald W Milligan.;Steve R Smith.;Wendy N Erber.;David Bareford.;Bridget S Wilkins.;John T Reilly.;Claire N Harrison.;Anthony R Green.; .; .; .
来源: Lancet. 2005年366卷9501期1945-53页
An acquired V617F mutation in JAK2 occurs in most patients with polycythaemia vera, but is seen in only half those with essential thrombocythaemia and idiopathic myelofibrosis. We aimed to assess whether patients with the mutation are biologically distinct from those without, and why the same mutation is associated with different disease phenotypes.
1946. Comparison of rapidly cycled tandem high-dose chemotherapy plus peripheral-blood stem-cell support versus dose-dense conventional chemotherapy for adjuvant treatment of high-risk breast cancer: results of a multicentre phase III trial.
作者: Ulrike Anneliese Nitz.;Svjetlana Mohrmann.;Johannes Fischer.;Walter Lindemann.;Wolfgang E Berdel.;Christian Jackisch.;Christoph Werner.;Carsten Ziske.;Hartmut Kirchner.;Bernd Metzner.;Rainer Souchon.;Ute Ruffert.;Gerhart Schütt.;Anke Pollmanns.;Hans Joachim Schmoll.;Constantin Middecke.;Jörg Baltzer.;Iris Schrader.;Herrmann Wiebringhaus.;Yon Ko.;Siegfried Rösel.;Thomas Schwenzer.;Peter Wernet.;Axel Hinke.;Hans Georg Bender.;Markus Frick.; .
来源: Lancet. 2005年366卷9501期1935-44页
Breast cancer with extensive axillary-lymph-node involvement has a poor prognosis after conventional treatment. In trials with historical controls, high-dose chemotherapy produced improved outcomes. We compared an intensive double-cycle high-dose chemotherapy regimen with an accelerated conventionally dosed regimen in high-risk breast cancer in a multicentre trial.
1947. Bypass versus angioplasty in severe ischaemia of the leg (BASIL): multicentre, randomised controlled trial.
作者: D J Adam.;J D Beard.;T Cleveland.;J Bell.;A W Bradbury.;J F Forbes.;F G R Fowkes.;I Gillepsie.;C V Ruckley.;G Raab.;H Storkey.; .
来源: Lancet. 2005年366卷9501期1925-34页
The treatment of rest pain, ulceration, and gangrene of the leg (severe limb ischaemia) remains controversial. We instigated the BASIL trial to compare the outcome of bypass surgery and balloon angioplasty in such patients.
1948. Safety and efficacy of zinc supplementation for children with HIV-1 infection in South Africa: a randomised double-blind placebo-controlled trial.
作者: Raziya Bobat.;Hoosen Coovadia.;Cindy Stephen.;Kimesh L Naidoo.;Neil McKerrow.;Robert E Black.;William J Moss.
来源: Lancet. 2005年366卷9500期1862-7页
Zinc deficiency is associated with impaired immune function and an increased risk of infection. Supplementation can decrease the incidence of diarrhoea and pneumonia in children in resource-poor countries. However, in children with HIV-1 infection, the safety of zinc supplementation is uncertain. We aimed to assess the role of zinc in HIV-1 replication before mass zinc supplementation is recommended in regions of high HIV-1 prevalence.
1949. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial.
作者: A Keech.;R J Simes.;P Barter.;J Best.;R Scott.;M R Taskinen.;P Forder.;A Pillai.;T Davis.;P Glasziou.;P Drury.;Y A Kesäniemi.;D Sullivan.;D Hunt.;P Colman.;M d'Emden.;M Whiting.;C Ehnholm.;M Laakso.; .
来源: Lancet. 2005年366卷9500期1849-61页
Patients with type 2 diabetes mellitus are at increased risk of cardiovascular disease, partly owing to dyslipidaemia, which can be amenable to fibrate therapy. We designed the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study to assess the effect of fenofibrate on cardiovascular disease events in these patients.
1950. Negative pressure wound therapy after partial diabetic foot amputation: a multicentre, randomised controlled trial.
Diabetic foot wounds, particularly those secondary to amputation, are very complex and difficult to treat. We investigated whether negative pressure wound therapy (NPWT) improves the proportion and rate of wound healing after partial foot amputation in patients with diabetes.
1951. Ertapenem versus piperacillin/tazobactam for diabetic foot infections (SIDESTEP): prospective, randomised, controlled, double-blinded, multicentre trial.
作者: Benjamin A Lipsky.;David G Armstrong.;Diane M Citron.;Alan D Tice.;David E Morgenstern.;Murray A Abramson.
来源: Lancet. 2005年366卷9498期1695-703页
Diabetic foot infections are a common and serious problem, yet few randomised trials of adequate quality have compared the efficacy of the various antibiotic regimens available for their treatment. Our aim was to assess the efficacy and safety of ertapenem versus piperacillin/tazobactam for foot infections.
1952. Early intravenous then oral metoprolol in 45,852 patients with acute myocardial infarction: randomised placebo-controlled trial.
作者: Z M Chen.;H C Pan.;Y P Chen.;R Peto.;R Collins.;L X Jiang.;J X Xie.;L S Liu.; .
来源: Lancet. 2005年366卷9497期1622-32页
Despite previous randomised trials of early beta-blocker therapy in the emergency treatment of myocardial infarction (MI), uncertainty has persisted about the value of adding it to current standard interventions (eg, aspirin and fibrinolytic therapy), and the balance of potential benefits and hazards is still unclear in high-risk patients.
1953. Addition of clopidogrel to aspirin in 45,852 patients with acute myocardial infarction: randomised placebo-controlled trial.
作者: Z M Chen.;L X Jiang.;Y P Chen.;J X Xie.;H C Pan.;R Peto.;R Collins.;L S Liu.; .
来源: Lancet. 2005年366卷9497期1607-21页
Despite improvements in the emergency treatment of myocardial infarction (MI), early mortality and morbidity remain high. The antiplatelet agent clopidogrel adds to the benefit of aspirin in acute coronary syndromes without ST-segment elevation, but its effects in patients with ST-elevation MI were unclear.
1954. Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer).
作者: Nick Thatcher.;Alex Chang.;Purvish Parikh.;José Rodrigues Pereira.;Tudor Ciuleanu.;Joachim von Pawel.;Sumitra Thongprasert.;Eng Huat Tan.;Kristine Pemberton.;Venice Archer.;Kevin Carroll.
来源: Lancet. 2005年366卷9496期1527-37页
This placebo-controlled phase III study investigated the effect on survival of gefitinib as second-line or third-line treatment for patients with locally advanced or metastatic non-small-cell lung cancer.
1955. Differences between organophosphorus insecticides in human self-poisoning: a prospective cohort study.
作者: Michael Eddleston.;Peter Eyer.;Franz Worek.;Fahim Mohamed.;Lalith Senarathna.;Ludwig von Meyer.;Edmund Juszczak.;Ariyasena Hittarage.;Shifa Azhar.;Wasantha Dissanayake.;M H Rezvi Sheriff.;Ladislaus Szinicz.;Andrew H Dawson.;Nick A Buckley.
来源: Lancet. 2005年366卷9495期1452-9页
Although more than 100 organophosphorus insecticides exist, organophosphorus poisoning is usually regarded as a single entity, distinguished only by the compound's lethal dose in animals. We aimed to determine whether the three most common organophosphorus insecticides used for self-poisoning in Sri Lanka differ in the clinical features and severity of poisoning they cause.
1956. Voriconazole versus a regimen of amphotericin B followed by fluconazole for candidaemia in non-neutropenic patients: a randomised non-inferiority trial.
作者: B J Kullberg.;J D Sobel.;M Ruhnke.;P G Pappas.;C Viscoli.;J H Rex.;J D Cleary.;E Rubinstein.;L W P Church.;J M Brown.;H T Schlamm.;I T Oborska.;F Hilton.;M R Hodges.
来源: Lancet. 2005年366卷9495期1435-42页
Voriconazole has proven efficacy against invasive aspergillosis and oesophageal candidiasis. This multicentre, randomised, non-inferiority study compared voriconazole with a regimen of amphotericin B followed by fluconazole for the treatment of candidaemia in non-neutropenic patients.
1957. Infliximab induction and maintenance therapy for moderate-to-severe psoriasis: a phase III, multicentre, double-blind trial.
作者: Kristian Reich.;Frank O Nestle.;Kim Papp.;Jean-Paul Ortonne.;Robert Evans.;Cynthia Guzzo.;Shu Li.;Lisa T Dooley.;Christopher E M Griffiths.; .
来源: Lancet. 2005年366卷9494期1367-74页
Tumour necrosis factor alpha (TNFalpha) is thought to play a part in the pathogenesis of psoriasis. We assessed the efficacy and safety of continuous treatment with infliximab, a monoclonal antibody that binds to and neutralises the activity of TNFalpha, in patients with psoriasis.
1958. Effect of BCG revaccination on incidence of tuberculosis in school-aged children in Brazil: the BCG-REVAC cluster-randomised trial.
作者: Laura C Rodrigues.;Susan M Pereira.;Sergio S Cunha.;Bernd Genser.;Maria Yury Ichihara.;Silvana C de Brito.;Miguel A Hijjar.;Ines Dourado.;Alvaro A Cruz.;Clemax Sant'Anna.;Ana Luiza Bierrenbach.;Mauricio L Barreto.
来源: Lancet. 2005年366卷9493期1290-5页
Many countries offer a second BCG vaccination to prevent tuberculosis, although there is little evidence of whether this confers additional protection. BCG vaccination is routine in Brazil but BCG revaccination procedures vary by state. We studied revaccination efficacy in two Brazilian cities with tuberculosis prevalence representative of Brazil.
1959. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial.
作者: John A Dormandy.;Bernard Charbonnel.;David J A Eckland.;Erland Erdmann.;Massimo Massi-Benedetti.;Ian K Moules.;Allan M Skene.;Meng H Tan.;Pierre J Lefèbvre.;Gordon D Murray.;Eberhard Standl.;Robert G Wilcox.;Lars Wilhelmsen.;John Betteridge.;Kåre Birkeland.;Alain Golay.;Robert J Heine.;László Korányi.;Markku Laakso.;Marián Mokán.;Antanas Norkus.;Valdis Pirags.;Toomas Podar.;André Scheen.;Werner Scherbaum.;Guntram Schernthaner.;Ole Schmitz.;Jan Skrha.;Ulf Smith.;Jan Taton.; .
来源: Lancet. 2005年366卷9493期1279-89页
Patients with type 2 diabetes are at high risk of fatal and non-fatal myocardial infarction and stroke. There is indirect evidence that agonists of peroxisome proliferator-activated receptor gamma (PPAR gamma) could reduce macrovascular complications. Our aim, therefore, was to ascertain whether pioglitazone reduces macrovascular morbidity and mortality in high-risk patients with type 2 diabetes.
1960. Post-surgery adjuvant therapy with intermediate doses of interferon alfa 2b versus observation in patients with stage IIb/III melanoma (EORTC 18952): randomised controlled trial.
作者: Alexander M M Eggermont.;Stefan Suciu.;Rona MacKie.;Wlodzimierz Ruka.;Alessandro Testori.;Wim Kruit.;Cornelis J A Punt.;Michelle Delauney.;François Sales.;Gerard Groenewegen.;Dirk J Ruiter.;Izabella Jagiello.;Konstantin Stoitchkov.;Ulrich Keilholz.;Danielle Lienard.; .
来源: Lancet. 2005年366卷9492期1189-96页
Individuals affected by melanoma with thick primary tumours or regional node involvement have a poor outlook, with only 30-50% alive at 5 years. High-dose and low-dose interferon alfa have been assessed for the treatment of these patients, with the former having considerable toxicity and a consistent effect on disease free survival, but not on overall survival, and the latter no consistent effect on either. Our aim was, therefore, to assess the effect of two regimens of interferon of intermediate dose versus observation alone on distant metastasis-free interval (DMFI) and overall survival in such patients.
|